A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA)
Conditions
COVID-19 Inpatient | COVID-19 Outpatient
Phase COVID-III
Volunteers
Health Professionals
What is the purpose of this trial?
This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
- Ages12 years and older
- GenderBoth
- Trial withGenentech, Inc.
- Start Date09/23/2020
- End Date07/30/2020
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigator
- Last Updated10/01/2020
- Study HIC#2000028556